Tissue Sample Collection Instructions

Overview document on how Signatera collections a FFPE sample.

Early reduction in ctDNA is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma patients

Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Signatera Patient Brochure: Discover a better way to help monitor your immunotherapy treatment

Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response

AACR 2021: Circulating tumor DNA predicts disease recurrence in ovarian cancer patients

Epithelial ovarian, fallopian tube, and peritoneal cancer (EOC) is the most lethal gynecologic malignancy with a 5-year survival rate of 47%.

AACR 2021: Correlation of variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors

Two metrics are commonly used to quantify tumor-specific variants in cell-free DNA (cfDNA): the variant allele frequency (VAF) and mean tumor molecules (MTM)/mL of plasma.